In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
While amyloid positron emission tomography (PET) was originally viewed as a diagnostic test to help detect Alzheimer’s disease, Jacob Dubroff, M.D., Ph.D., said the recently issued proposal from the Centers for Medicare and Medicaid Services (CMS) to address prior Medicare coverage restrictions for this imaging “opens the opportunity” for the use of amyloid PET to assess treatment efficacy.
In a recent interview, Dr. Dubroff said amyloid PET imaging may help physicians and patients navigate a shifting ratio of benefits and risks such as amyloid-related imaging abnormalities (ARIA) during the use of anti-amyloid therapies.
“If you already got the benefit of the drug and don’t need more treatment, it’s good to stop because you don’t want to have the risks. Risks could be more side effects, hospitalizations, and more cost. I don’t know exactly how much amyloid PET imaging will be reimbursed for but hypothetically, let’s say it’s $2,000 or $3,000. If you can prevent an admission for $20,000, that is money well spent,” noted Dr. Dubroff, the modality chief of nuclear medicine and therapy, and associate professor of radiology at the Hospital of the University of Pennsylvania.
(Editor’s note: For related content, see “CMS Proposes Lift of Coverage Restrictions on PET imaging for Alzheimer’s Disease” and “Hybrid PET/MRI Assessment with Hippocampal Radiomics May Facilitate Early Alzheimer’s Diagnosis.”)
Dr. Dubroff emphasized the amyloid PET scan represents “an elegant, well-tolerated safe test” that can be utilized for diagnosis as well as the assessment of treatment effectiveness. While noting that the CMS proposal provides hope for improved Medicare coverage of amyloid PET imaging for patients with Alzheimer’s disease, Dr. Dubroff said balancing the benefits and risks with the considerable costs of anti-amyloid therapies and imaging will be a challenging conundrum.
“If you open the floodgates and allow all the testing and all the treatment, that is going to be a lot of money,” noted Dr. Dubroff. “How do we do this in a way that makes sense where we can get the most benefit out of imaging and the drug?”
For more insights from Dr. Dubroff, watch the video below.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.